blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3268474

EP3268474 - OLIGONUCLEOTIDES MATCHING COL7A1 EXON 73 FOR EPIDERMOLYSIS BULLOSA THERAPY [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  03.04.2021
Database last updated on 04.11.2024
FormerThe patent has been granted
Status updated on  24.04.2020
FormerGrant of patent is intended
Status updated on  17.12.2019
FormerExamination is in progress
Status updated on  07.12.2019
FormerGrant of patent is intended
Status updated on  03.09.2019
FormerExamination is in progress
Status updated on  21.09.2018
FormerRequest for examination was made
Status updated on  15.12.2017
FormerThe international publication has been made
Status updated on  01.02.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024  [2024/42]
Applicant(s)For all designated states
Wings Therapeutics, Inc.
2600 Tenth Street, No.435
Berkeley, CA 94710 / US
[2019/35]
Former [2018/03]For all designated states
ProQR Therapeutics II B.V.
Zernikedreef 9
2333 CK Leiden / NL
Inventor(s)01 / HAISMA, Elisabeth, Marlene
Pahudstraat 50
2593 TH Den Haag / NL
02 / POTMAN, Marko
Aert van Neslaan 62
2341 HX Oegstgeest / NL
03 / BEUMER, Wouter
Jacob Catsstraat 12
2274 GW Voorburg / NL
04 / BRINKS, Vera
Zwanenzijde 7
2317 XB Leiden / NL
 [2018/03]
Representative(s)Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
[2020/22]
Former [2018/03]Spinner, David Richard, et al
Greaves Brewster LLP
Copa House
Station Road
Cheddar, Somerset BS27 3AH / GB
Application number, filing date16709465.511.03.2016
[2018/03]
WO2016EP55360
Priority number, dateGB2015000412411.03.2015         Original published format: GB 201504124
[2018/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016142538
Date:15.09.2016
Language:EN
[2016/37]
Type: A1 Application with search report 
No.:EP3268474
Date:17.01.2018
Language:EN
The application published by WIPO in one of the EPO official languages on 15.09.2016 takes the place of the publication of the European patent application.
[2018/03]
Type: B1 Patent specification 
No.:EP3268474
Date:27.05.2020
Language:EN
[2020/22]
Search report(s)International search report - published on:EP15.09.2016
ClassificationIPC:C12N15/113, A61K31/712, A61K31/7125
[2018/03]
CPC:
C12N15/113 (EP,EA,IL,US); C12N15/10 (IL); C12N15/1138 (IL,KR);
A61K31/712 (IL,KR); A61K31/7125 (IL,KR); C12N2310/11 (EP,EA,IL,KR,US);
C12N2310/315 (EP,EA,IL,KR,US); C12N2310/321 (EA,IL,KR,US); C12N2310/346 (EP,EA,IL,KR,US);
C12N2310/3521 (IL,KR); C12N2320/33 (EP,EA,IL,KR,US) (-)
C-Set:
C12N2310/321, C12N2310/3521 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/03]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:OLIGONUKLEOTIDE IM ZUSAMMENHANG MIT EXON 73 IN COL7A1 ZUR EPIDERMOLYSIS-BULLOSA-THERAPIE[2018/03]
English:OLIGONUCLEOTIDES MATCHING COL7A1 EXON 73 FOR EPIDERMOLYSIS BULLOSA THERAPY[2018/03]
French:OLIGONUCLÉOTIDES CORRESPONDANT À L'EXON 73 DE COL7A1 POUR LA THÉRAPIE DE L'ÉPIDERMOLYSE BULLEUSE[2018/03]
Entry into regional phase06.10.2017National basic fee paid 
06.10.2017Designation fee(s) paid 
06.10.2017Examination fee paid 
Examination procedure11.01.2017Request for preliminary examination filed
International Preliminary Examining Authority: EP
27.09.2017Date on which the examining division has become responsible
06.10.2017Examination requested  [2018/03]
10.11.2017Amendment by applicant (claims and/or description)
20.09.2018Despatch of a communication from the examining division (Time limit: M04)
11.10.2018Reply to a communication from the examining division
04.09.2019Communication of intention to grant the patent
06.12.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
18.12.2019Communication of intention to grant the patent
07.04.2020Receipt of the translation of the claim(s)
15.04.2020Fee for grant paid
15.04.2020Fee for publishing/printing paid
Divisional application(s)EP20175344.9  / EP3763816
Opposition(s)02.03.2021No opposition filed within time limit [2021/18]
Fees paidRenewal fee
13.03.2018Renewal fee patent year 03
13.03.2019Renewal fee patent year 04
12.03.2020Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL27.05.2020
CY27.05.2020
EE27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MK27.05.2020
MT27.05.2020
RO27.05.2020
RS27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
[2024/42]
Former [2024/22]AL27.05.2020
CY27.05.2020
EE27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
MK27.05.2020
RO27.05.2020
RS27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
Former [2023/30]AL27.05.2020
CY27.05.2020
EE27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
RO27.05.2020
RS27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
Former [2021/45]AL27.05.2020
EE27.05.2020
LT27.05.2020
LV27.05.2020
MC27.05.2020
RO27.05.2020
RS27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
Former [2021/09]AL27.05.2020
EE27.05.2020
LT27.05.2020
LV27.05.2020
RO27.05.2020
RS27.05.2020
SM27.05.2020
BG27.08.2020
GR28.08.2020
Former [2021/04]AL27.05.2020
LT27.05.2020
LV27.05.2020
RS27.05.2020
BG27.08.2020
GR28.08.2020
Former [2021/01]LT27.05.2020
LV27.05.2020
RS27.05.2020
BG27.08.2020
GR28.08.2020
Former [2020/51]LT27.05.2020
LV27.05.2020
RS27.05.2020
GR28.08.2020
Former [2020/50]LT27.05.2020
LV27.05.2020
GR28.08.2020
Former [2020/47]LT27.05.2020
Cited inInternational search[ID]WO2013053819  (INST NAT SANTE RECH MED [FR]) [ID] 1-11,15 * the whole document *;
 [X]  - "Human tumour suppression/reversion-related DNA sequence SeqID1712.", Geneseq, (20040415), Database accession no. ADI49209, URL: EBI, XP002758383 [X] 1-7,12-14 * sequence . *
 [X]  - "Human organ specific protein related DNA SEQ:60255.", Geneseq, (20110203), Database accession no. AUN58914, URL: EBI, XP002758384 [X] 1-7,12-14 * sequence . *
 [X]  - "Sequence 513357 from Patent EP2213738.", EMBL, (20100818), Database accession no. HD636641, URL: EBI, XP002758385 [X] 1-7,12-14 * sequence . *
 [A]  - TURCZYNSKI SANDRINA ET AL, "Antisense-mediated exon skipping to reframe transcripts", EXON SKIPPING : METHODS AND PROTOCOLS; [METHODS IN MOLECULAR BIOLOGY; ISSN 1940-6029; VOL. 867], HUMANA PR, NEW YORK [U.A.], (2012), vol. 867, ISBN 978-1-61779-766-8, pages 221 - 238, XP008177335 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1007/978-1-61779-767-5_15
 [A]  - NINGNING DANG ET AL, "Mutation analysis and characterization of COL7A1 mutations in dystrophic epidermolysis bullosa", EXPERIMENTAL DERMATOLOGY, (20080701), vol. 17, no. 7, doi:10.1111/j.1600-0625.2008.00723.x, ISSN 0906-6705, pages 553 - 568, XP055019941 [A] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1600-0625.2008.00723.x
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.